1.Associations between serum 25-hydroxyvitamin D3 level and skeletal muscle mass and lower limb muscle strength in Japanese middle-aged subjects.
Akiko KUWABARA ; Naoko TSUGAWA ; Hiroshi KONDO ; Misora AO ; Hitomi FUJIWARA ; Natsuki HOSOKAWA ; Shiho MATSUMOTO ; Kiyoshi TANAKA ; Tetsuo NAKANO
Osteoporosis and Sarcopenia 2017;3(1):53-58
OBJECTIVES: One of the important risk factors of falling is decreased muscle mass and muscle strength. Recently, there has been an increasing concern on the role of vitamin D in muscle strength and physical activity. Aim of our study is to examine the relationships between vitamin D status and muscle mass and muscle strength in middle-aged healthy adults. METHODS: Subjects were 40 healthy volunteers aged 42.0 ± 10.6 years old. Evaluation was made for serum vitamin D₃ metabolites including 25-hydroxyvitamin D₃ [25(OH)D₃] and 24,25-dihydroxyvitamin D₃ [24,25(OH)₂D₃] concentrations, lower limb muscle strength, and dietary intake by food frequency questionnaire. Body composition was measured by dual-energy X-ray absorptiometry (DXA), and appendicular skeletal mass index (ASMI) was calculated as skeletal muscle mass/squared height. RESULTS: 70% of the subjects had vitamin D insufficiency/deficiency (serum total 25(OH)D < 20 ng/mL), and female subjects had significantly lower serum total 25(OH)D level compared with males. Vitamin D insufficiency/deficiency group had significantly higher body fat, lower SMI and muscle strength, probably reflecting higher percentage of female subjects. Serum vitamin D₃ metabolites levels were significantly correlated with whole and site-specific ASMI, and lower limb muscle strength, except for the correlation between serum 24,25(OH)₂D₃ concentration and lower limb muscle strength. In addition, serum 25(OH)D₃ level was a positive significant predictor for both ASMI and lower limb muscle strength, while serum 24,25(OH)₂D₃ level was not their significant predictor. CONCLUSIONS: Serum 25(OH)D₃ level was significantly correlated with both skeletal muscle mass and lower limb muscle strength.
Absorptiometry, Photon
;
Accidental Falls
;
Adipose Tissue
;
Adult
;
Asian Continental Ancestry Group*
;
Body Composition
;
Calcifediol*
;
Female
;
Healthy Volunteers
;
Humans
;
Lower Extremity*
;
Male
;
Motor Activity
;
Muscle Strength*
;
Muscle, Skeletal*
;
Risk Factors
;
Vitamin D
;
Vitamins
2.High expression of folate receptor alpha is associated with poor prognosis in patients with cervical cancer
Shu YAZAKI ; Yuki KOJIMA ; Hiroshi YOSHIDA ; Shigemasa TAKAMIZAWA ; Rui KITADAI ; Tadaaki NISHIKAWA ; Tatsunori SHIMOI ; Kazuki SUDO ; Ayumi SAITO ; Hitomi Sumiyoshi OKUMA ; Maki TANIOKA ; Emi NOGUCHI ; Masaya UNO ; Mitsuya ISHIKAWA ; Tomoyasu KATO ; Yasuhiro FUJIWARA ; Yuichiro OHE ; Kan YONEMORI
Journal of Gynecologic Oncology 2022;33(6):e82-
Objective:
Folate receptor α (FRα) is a membrane protein expressed in various solid tumors but has limited expression in normal cells. Therefore, FRα is an attractive target for cancer treatment. This study aimed to investigate the relationship between FRα expression and the clinicopathological characteristics and survivals of cervical cancer.
Methods:
This retrospective study included patients with cervical cancer who underwent primary surgery between 2000 and 2020 at our institution. Immunohistochemical staining of FRα was performed using an anti-folate-binding protein/FBP antibody. FRα-positive staining was defined as ≥5% of tumor staining and FRα-high as ≥50% tumor staining with ≥2+ intensity. The association between FRα expression and survival was assessed using multivariate Cox regression analysis, adjusting for established prognostic factors.
Results:
Overall, 123 patients were identified, and 140 tumor samples, including 17 paired primary and metastatic samples, were evaluated. As histological types, 67 patients had squamous cell carcinoma (SCC), and 56 patients had non-SCC. All primary tumors were FRα-positive. High FRα expression was observed in 25% of the cases and differed according to histology (SCC vs. non-SCC, 14.9% vs. 37.5%, p=0.004). FRα expression was significantly higher in metastatic tumors than in primary (170 [IQR, 140–205] vs. 125 [IQR, 110–150], p=0.0006). High FRα expression was significantly associated with worse overall survival (hazard ratio, 6.73; 95% confidence interval, 2.21–20.53; p=0.001).
Conclusion
In cervical cancer, FRα expression was elevated in metastatic tumors and high expression was associated with a worse prognosis. Our study supports the development of FRα-targeted therapy for advanced cervical cancer.